* Gossamer Bio Inc is expected to show a rise in quarterly revenue when it reports results on November 7 (estimated) for the period ending September 30 2024
* The San Diego California-based company is expected to report revenue of $7.7 million, according to the mean estimate from 9 analysts, based on LSEG data.
* LSEG's mean analyst estimate for Gossamer Bio Inc is for a loss of 15 cents per share.
* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy," 3 "hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in the last three months.
* Wall Street's median 12-month price target for Gossamer Bio Inc is 7.00, above its last closing price of $0.88.
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER STARMINESM LSEG IBES ACTUAL BEAT, SURPRI
ENDING ARTESTIMAT ESTIMATE MET, SE %
E® MISSED
Jun. 30 2024 0.31 0.23 0.22 Missed -3.9
Jan. 1 2024 -0.19 -0.19 -0.19 Met -0.5
Dec. 31 2023 -0.19 -0.21 -0.21 Met -1
Sep. 30 2023 -0.24 -0.26 -0.21 Beat 17.8
Jan. -0.48 -0.49 -0.45 Beat 8
1 0001
Mar. 31 2023 -0.52 -0.53 -0.52 Beat 1.8
Jan. 1 0001 -0.62 -0.62 -0.59 Beat 5.3
Sep. 30 2022 -0.66 -0.64 -0.65 Missed -2.3
This summary was machine generated November 6 at 14:30 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
Comments